{
  "docId": "019dd923-622c-750b-8b9a-2a2468219173",
  "docSlug": "ce565b841c40",
  "documentTitle": "Nevro Corp. (NVRO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Kir Kahlon",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2021-01-07 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 154,
  "pageCount": 239,
  "prevPage": 153,
  "nextPage": 155,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "Uses direct quotes from KOLs to undermine company narrative.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "bullet_list",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-2a2468219173/154",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173#slide-154",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Nevro calling PDN a new indication is \"so stupid\" and \"just dopey\" according to KOL's, given that it's widely coded today as neuropathy.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b343-b3812607c821",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.85,
        "x": 0.05,
        "y": 0.39
      },
      "kind": "list",
      "text": "Stimulators have been extensively implanted for decades for PDN and the indication is already reimbursed by Medicare",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8237b947-c845-4fec-b1ac-b1417efc25fe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.85,
        "x": 0.05,
        "y": 0.67
      },
      "kind": "list",
      "text": "Nevro calling PDN a new indication is \"so stupid\" and \"just dopey\" according to KOL's, given that it's widely coded today as neuropathy.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "caeb7573-a420-49ac-a7e7-0426f8d398d7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.13
      },
      "kind": "paragraph",
      "text": "We investigated Nevro's PDN study and the claims that it expands the market for their high frequency device. Our research found widespread skepticism and outright ridicule among KOL's and Nevro's former executives and sales reps at the notion that PDN is a meaningful new commercial opportunity. One KOL after another – including some of Nevro's most loyal users – stated that spinal cord stimulation has already been used for decades for PDN and is already approved by Medicare, blasting the company's claims that it's a \"new indication\" as \"so stupid\" and \"just dopey.\" One stated that Nevro's PDN study has \"value to Wall Street and no one else.\"",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dbf07607-45a6-43a7-aaa3-e4b53333ce55",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.85,
        "x": 0.08,
        "y": 0.46
      },
      "kind": "quote",
      "text": "\"So here's the deal with diabetic neuropathy. I used to lecture on this in the 90's. I've used stimulators for PDN for 25 years. Nevro's PDN study is not telling us anything new at all. The literature was always there. There were studies in the 90's. Bottom line is, you just call it neuropathic leg of the pain and Medicare pays for it. We were doing that, are doing that, and there's nothing new about it. The study has value to Wall Street and no one else. Any doctor who knows stimulators already uses them for diabetic neuropathy.\" – KOL and high volume implanter",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "14ab51bb-b153-44b6-a115-8c1ef7d153a3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.85,
        "x": 0.08,
        "y": 0.62
      },
      "kind": "quote",
      "text": "\"In the 1980's, half of the patients we implanted with stimulators were for PDN.\" – High volume Nevro user",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2f6f1e11-9511-4f34-9bfe-ca44f266181e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.85,
        "x": 0.08,
        "y": 0.74
      },
      "kind": "quote",
      "text": "\"Nevro saying they have this diabetic peripheral neuropathy indication is so stupid. We've been doing PDN treatment with stimulators forever. All they did was say, it's off-label. We're going to get it so that it's on-label. But if I have a diabetic that has neuropathy, we just code it as neuropathy, lower extremity. We don't call it PDN So what Nevro is doing is just dopey. Here's the thing: everybody is treating diabetics with spinal cord stimulation already yet Nevro's saying \"Look what we invented!\" We've been using stim forever for diabetics with neuropathy. This has been around forever.\" – KOL",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c481ff66-f660-411d-a426-a4b392d47f9f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "\"So here's the deal with diabetic neuropathy. I used to lecture on this in the 90's. I've used stimulators for PDN for 25 years. Nevro's PDN study is not telling us anything new at all... The study has value to Wall Street and no one else.\" — KOL and high volume implanter; \"In the 1980's, half of the patients we implanted with stimulators were for PDN.\" — High volume Nevro user; \"Nevro saying they have this diabetic peripheral neuropathy indication is so stupid. We've been doing PDN treatment with stimulators forever... This has been around forever.\" — KOL",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b343-b7b7e802b131",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.2,
        "x": 0.05,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "Source: Consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b83a8e17-678e-4821-bdc5-970227935712",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.9,
        "x": 0.05,
        "y": 0.09
      },
      "kind": "title",
      "text": "11. TAM expansion and growth from painful diabetic neuropathy (PDN) and other new indications are a mirage",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a94fe3ca-dd16-4739-b3bb-32a62f8a4675",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.05,
        "y": 0.04
      },
      "kind": "title",
      "text": "Scorpion Capital | Nevro (NYSE: NVRO)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9c635702-28e2-42c4-aebf-4cf39799e171",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "c3a53a0f-aaed-48ff-8c44-d7fd4ae9e871",
      "evidence": "The slide explicitly frames the company's claims as a 'mirage' and 'stupid' based on expert testimony to expose a contradiction in the company's growth narrative.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}